Smokeless tobacco alternatives company Black Buffalo Inc announced on Tuesday that it has partnered with Sanova LLC, a New York-based scientific and regulatory consulting agency, to support its regulatory, compliance, and scientific research programmes.
Sanova has extensive experience helping nicotine manufacturers navigate complex regulatory frameworks, including the US Food and Drug Administration's (FDA) Premarket Tobacco Product Application (PMTA) and Modified Risk Tobacco Product (MRTP) pathways. Sanova's partnership with Black Buffalo includes helping guide the company through the final and most critical phases of FDA review, including substantive scientific review, a rigorous process that evaluates the health impact and overall safety profile of nicotine products intended for adult use.
Kellsi Booth, Black Buffalo's chief legal officer, said: "The Sanova team combines decades of FDA and industry insight with a forward-looking approach. Enlisting Sanova as a key partner represents our commitment to full regulatory transparency, scientific excellence, and responsible innovation within the nicotine space."
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform